Leerink Swann Initiates Trillium Therapeutics At Outperform

Loading...
Loading...
Analysts at Leerink Swann initiated coverage on
Trillium Therapeutics IncTRIL
with a Outperform rating. The target price for Trillium Therapeutics is set to $29. Trillium Therapeutics shares have gained 132.57 percent over the past 52 weeks, while the S&P 500 index has surged 13.28 percent in the same period. Trillium Therapeutics' shares closed at $24.21 on Friday.
Posted In: InitiationAnalyst RatingsLeerink Swann
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...